1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > PharmaPoint: Ulcerative Colitis - Current and Future Players

PharmaPoint: Ulcerative Colitis - Current and Future Players

Summary

GlobalData has released its pharma report, “PharmaPoint: Ulcerative Colitis - Current and Future Players”. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Ulcerative Colitis Market. The report identifies and analyses the key companies shaping and driving the global Ulcerative Colitis market. The report provides insight into the competitive Ulcerative Colitis landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData’s team of industry experts.

Scope

- Investigation of current and future market competition for Ulcerative Colitis
- Competitor assessment
- Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
- Strategic assessment of Ulcerative Colitis sector through market impact analysis, future market scenario and company analysis

Reasons to buy

- Gain a high level view of the trends shaping and driving Ulcerative Colitis market
- Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
- Create an effective counter-strategy to gain a competitive advantage against those currently in the market
- What’s the next big thing in the global Ulcerative Colitis market landscape? Identify, understand and capitalize.

Table Of Contents

PharmaPoint: Ulcerative Colitis - Current and Future Players
1 Table of Contents

2 Introduction 10
2.1 Catalyst 10
2.2 Related Reports 10
2.3 Upcoming Related Reports 12
3 Market Outlook 13
3.1 Global Markets 13
3.1.1 Forecast 13
3.1.2 Drivers and Barriers - Global Issues 17
4 Current and Future Players 22
4.1 Overview 22
4.2 Trends in Corporate Strategy 25
4.3 Company Profiles 26
4.3.1 Johnson and Johnson 26
4.3.2 AbbVie 28
4.3.3 Takeda Pharmaceuticals 30
4.3.4 Warner Chilcott 32
4.3.5 Salix Pharmaceuticals/Santarus 34
4.3.6 Shire Pharmaceuticals 36
4.3.7 Ferring Pharmaceuticals 38
4.3.8 Pfizer 39
4.3.9 InDeX Pharmaceuticals 41
5 Appendix 44
5.1 Bibliography 44
5.2 Abbreviations 44
5.3 Methodology 46
5.4 Forecasting Methodology 46
5.4.1 Diagnosed UC Patients 46
5.4.2 Percent Drug-Treated Patients 47
5.4.3 General Pricing Assumptions 47
5.4.4 Generic Erosion 48
5.5 Physicians and Specialists Included in This Study 48
5.6 Primary Research - Prescriber Survey 49
5.7 About the Authors 50
5.7.1 Author 50
5.7.2 Global Head of Healthcare 51
5.8 About GlobalData 52
5.9 Disclaimer 52

1.1 List of Tables

Table 1: Global Sales Forecasts ($m) for UC, 2012-2022 15
Table 2: Global UC Market - Drivers and Barriers, 2012-2022 17
Table 3: Key Companies in the UC Market, 2012-2022 23
Table 4: JandJ's UC Portfolio Assessment, 2014 27
Table 5: JandJ's SWOT Analysis in UC, 2014 28
Table 6: AbbVie's UC Portfolio Assessment, 2014 29
Table 7: AbbVie's UC SWOT Analysis, 2014 30
Table 8: Takeda Pharmaceuticals' UC Portfolio Assessment, 2014 31
Table 9: Takeda's UC SWOT Analysis, 2014 32
Table 10: Warner Chilcott's UC Portfolio Assessment, 2014 33
Table 11: Warner Chilcott's UC SWOT Analysis, 2014 34
Table 12: Salix Pharmaceuticals/Santarus UC Portfolio Assessment, 2013 35
Table 13: Salix Pharmaceuticals/Santarus UC SWOT Analysis, 2014 36
Table 14: Shire Pharmaceuticals' UC Portfolio Assessment, 2014 37
Table 15: Shire Pharmaceuticals' UC SWOT Analysis, 2014 37
Table 16: Ferring Pharmaceuticals' UC Portfolio Assessment, 2013 38
Table 17: Ferring Pharmaceutical's UC SWOT Analysis, 2014 39
Table 18: Pfizer's UC Portfolio Assessment, 2014 40
Table 19: Pfizer's UC SWOT Analysis, 2014 41
Table 20: InDeX Pharmaceuticals' UC Portfolio Assessment, 2013 42
Table 21: InDeX Pharmaceuticals' UC SWOT Analysis, 2014 43
Table 22: Physicians Surveyed, By Country 49

1.2 List of Figures

Figure 1: Global Sales for UC by Region, 2012 -2022 16
Figure 2: Company Portfolio Gap Analysis in UC, 2012-2022 24

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
2016 Virology and Bacteriology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales and Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

2016 Virology and Bacteriology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales and Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

  • $ 54501
  • Industry report
  • October 2016
  • by Venture Planning Group

This unique 33-country survey from VPGMarketResearch.com contains over 2,100 pages, 875 tables and provides data and analysis not available from any other published source. The survey is designed to assist ...

2016 Infectious Disease Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

2016 Infectious Disease Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

  • $ 54501
  • Industry report
  • October 2016
  • by Venture Planning Group

This unique 33-country survey from VPGMarketResearch.com contains over 2,100 pages, 875 tables and provides data and analysis not available from any other published source. The survey is designed to assist ...

2016 Microbiology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Molecular Diagnostic, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, and Immunodiagnostic Tests

2016 Microbiology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Molecular Diagnostic, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, and Immunodiagnostic Tests

  • $ 47500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,000 pages and 550 tables, and provides granular data and analysis not available from any other published source. The survey is designed ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.